Notes
The study was funded by Sunovion Pharmaceuticals, Inc.
Reference
Rajagopalan K, et al. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics : 11 Apr 2016. Available from: URL: http://doi.org/10.1007/s40273-016-0405-0
Rights and permissions
About this article
Cite this article
Lurasidone a cost-saving treatment option in schizophrenia. PharmacoEcon Outcomes News 751, 18 (2016). https://doi.org/10.1007/s40274-016-2978-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2978-4